Reducing the risk of obesity

Defining the role of weight loss drugs

Hua Ling, Thomas L. Lenz, Tammy L. Burns, Daniel E. Hilleman

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The prevalence of obesity has increased dramatically in the past 20 years. As a public health concern, obesity is associated with a health care resource burden that is quickly approaching that associated with tobacco use. Although lifestyle intervention (diet and exercise) remains the mainstay of treatment of obesity, its effectiveness is limited by poor long-term adherence. Drug therapy has historically been unsuccessful in producing sustained weight loss. Many older weight loss drugs have adverse benefit-to-risk profiles. This review provides an overview of nonpharmacologic interventions for weight loss. The safety and efficacy of older weight loss drugs, as well as current data related to lorcaserin, phentermine/topiramate, and naltrexone-bupropion, are evaluated. Although associated with modest weight loss and some improvement in adverse obesity-related metabolic effects, none of these drugs has been demonstrated to reduce mortality. In addition, the long-term safety of these drugs remains largely unknown. Bariatric surgery is an option for patients with morbid obesity who have failed conventional treatment.

Original languageEnglish
Pages (from-to)1308-1321
Number of pages14
JournalPharmacotherapy
Volume33
Issue number12
DOIs
StatePublished - 2013

Fingerprint

Anti-Obesity Agents
Obesity
Weight Loss
Phentermine
Safety
Bupropion
Naltrexone
Bariatric Surgery
Morbid Obesity
Health Resources
Tobacco Use
Pharmaceutical Preparations
Life Style
Public Health
Exercise
Diet
Delivery of Health Care
Drug Therapy
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Reducing the risk of obesity : Defining the role of weight loss drugs. / Ling, Hua; Lenz, Thomas L.; Burns, Tammy L.; Hilleman, Daniel E.

In: Pharmacotherapy, Vol. 33, No. 12, 2013, p. 1308-1321.

Research output: Contribution to journalReview article

@article{fdd98b77d8934638825c34525296b2c2,
title = "Reducing the risk of obesity: Defining the role of weight loss drugs",
abstract = "The prevalence of obesity has increased dramatically in the past 20 years. As a public health concern, obesity is associated with a health care resource burden that is quickly approaching that associated with tobacco use. Although lifestyle intervention (diet and exercise) remains the mainstay of treatment of obesity, its effectiveness is limited by poor long-term adherence. Drug therapy has historically been unsuccessful in producing sustained weight loss. Many older weight loss drugs have adverse benefit-to-risk profiles. This review provides an overview of nonpharmacologic interventions for weight loss. The safety and efficacy of older weight loss drugs, as well as current data related to lorcaserin, phentermine/topiramate, and naltrexone-bupropion, are evaluated. Although associated with modest weight loss and some improvement in adverse obesity-related metabolic effects, none of these drugs has been demonstrated to reduce mortality. In addition, the long-term safety of these drugs remains largely unknown. Bariatric surgery is an option for patients with morbid obesity who have failed conventional treatment.",
author = "Hua Ling and Lenz, {Thomas L.} and Burns, {Tammy L.} and Hilleman, {Daniel E.}",
year = "2013",
doi = "10.1002/phar.1277",
language = "English",
volume = "33",
pages = "1308--1321",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "12",

}

TY - JOUR

T1 - Reducing the risk of obesity

T2 - Defining the role of weight loss drugs

AU - Ling, Hua

AU - Lenz, Thomas L.

AU - Burns, Tammy L.

AU - Hilleman, Daniel E.

PY - 2013

Y1 - 2013

N2 - The prevalence of obesity has increased dramatically in the past 20 years. As a public health concern, obesity is associated with a health care resource burden that is quickly approaching that associated with tobacco use. Although lifestyle intervention (diet and exercise) remains the mainstay of treatment of obesity, its effectiveness is limited by poor long-term adherence. Drug therapy has historically been unsuccessful in producing sustained weight loss. Many older weight loss drugs have adverse benefit-to-risk profiles. This review provides an overview of nonpharmacologic interventions for weight loss. The safety and efficacy of older weight loss drugs, as well as current data related to lorcaserin, phentermine/topiramate, and naltrexone-bupropion, are evaluated. Although associated with modest weight loss and some improvement in adverse obesity-related metabolic effects, none of these drugs has been demonstrated to reduce mortality. In addition, the long-term safety of these drugs remains largely unknown. Bariatric surgery is an option for patients with morbid obesity who have failed conventional treatment.

AB - The prevalence of obesity has increased dramatically in the past 20 years. As a public health concern, obesity is associated with a health care resource burden that is quickly approaching that associated with tobacco use. Although lifestyle intervention (diet and exercise) remains the mainstay of treatment of obesity, its effectiveness is limited by poor long-term adherence. Drug therapy has historically been unsuccessful in producing sustained weight loss. Many older weight loss drugs have adverse benefit-to-risk profiles. This review provides an overview of nonpharmacologic interventions for weight loss. The safety and efficacy of older weight loss drugs, as well as current data related to lorcaserin, phentermine/topiramate, and naltrexone-bupropion, are evaluated. Although associated with modest weight loss and some improvement in adverse obesity-related metabolic effects, none of these drugs has been demonstrated to reduce mortality. In addition, the long-term safety of these drugs remains largely unknown. Bariatric surgery is an option for patients with morbid obesity who have failed conventional treatment.

UR - http://www.scopus.com/inward/record.url?scp=84897500490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897500490&partnerID=8YFLogxK

U2 - 10.1002/phar.1277

DO - 10.1002/phar.1277

M3 - Review article

VL - 33

SP - 1308

EP - 1321

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 12

ER -